Trial Profile

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XmAb 541 (Primary) ; XmAb 541 (Primary)
Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer
Focus Adverse reactions; First in man
Sponsors Xencor

27 Feb 2025 According to a Xencor media release, the company announced that characterization of target dose levels is anticipated to begin during 2025.
06 Sep 2024 According to a Xencor media release, the company will host Research & Development Webcast and Conference call on monday, September 9, 2024, at 8:00 a.m. ET (5:00 a.m. PT), to provide updates on continued progress in dose escalation with first-in-class oncology programs.
09 May 2024 According to a Xencor media release first patient was recently dosed in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com